Amount of qualified individuals: CDEC discussed the uncertainty in the number of people with reasonably significant to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some sufferers who will be labeled as possessing moderate or moderate disease may have a serious bleeding https://hemgenix16371.losblogos.com/34797889/the-smart-trick-of-hemgenix-that-nobody-is-discussing